The role of radiotherapy in the management of POEMS syndrome

Yang Gun Suh, Young Suk Kim, Chang Ok Suh, Yu R.i. Kim, June Won Cheong, Jin S.eok Kim, Jaeho Cho

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

BACKGROUND: POEMS syndrome is a paraneoplastic syndrome caused by an underlying plasma cell proliferative disease. In this study, we examined the treatment outcomes and role of radiotherapy in the management of POEMS syndrome.

METHODS: In total, 33 patients diagnosed with POEMS syndrome were analyzed. These patients presented with osteosclerotic myeloma (OSM, n = 13), Castleman's disease (CD, n = 4), OSM with CD (n = 10), and vascular endothelial growth factor elevation without gross lesions (VEGFe, n = 6), respectively. The patients were treated by radiotherapy alone (n = 4), chemotherapy alone (n = 16), or a combination thereof (n = 9).

RESULTS: The clinical response rates of radiotherapy, chemotherapy, and radiotherapy plus chemotherapy were 75%, 69%, and 89%, respectively. In addition, the hematologic response rates were 50%, 69%, and 71%, respectively. Among the six patients with limited multiple lesions who underwent radiotherapy, the clinical symptoms were improved in five patients after radiotherapy. The median progression-free survival (PFS) was 51 months, and the median overall survival (OS) was 65 months. In univariate analysis, the administration of chemotherapy was significantly associated with better PFS (p = 0.007) and OS (p = 0.020). In contrast, underlying VEGFe was a significant factor worsening PFS (p = 0.035) and OS (p = 0.008).

CONCLUSIONS: Radiotherapy produces a reliable clinical response and is effective in improving POEMS-associated symptoms that are refractory to chemotherapy in selected patients with clustered or limited multiple lesions that can be covered by single radiation field.

Original languageEnglish
Number of pages1
JournalRadiation oncology (London, England)
Volume9
DOIs
Publication statusPublished - 2014 Jan 1

Fingerprint

POEMS Syndrome
Radiotherapy
Drug Therapy
Disease-Free Survival
Survival
Giant Lymph Node Hyperplasia
Paraneoplastic Syndromes
Plasma Cells
Vascular Endothelial Growth Factor A
Radiation

All Science Journal Classification (ASJC) codes

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

@article{f592945027784fec9f93b13d1bf72771,
title = "The role of radiotherapy in the management of POEMS syndrome",
abstract = "BACKGROUND: POEMS syndrome is a paraneoplastic syndrome caused by an underlying plasma cell proliferative disease. In this study, we examined the treatment outcomes and role of radiotherapy in the management of POEMS syndrome.METHODS: In total, 33 patients diagnosed with POEMS syndrome were analyzed. These patients presented with osteosclerotic myeloma (OSM, n = 13), Castleman's disease (CD, n = 4), OSM with CD (n = 10), and vascular endothelial growth factor elevation without gross lesions (VEGFe, n = 6), respectively. The patients were treated by radiotherapy alone (n = 4), chemotherapy alone (n = 16), or a combination thereof (n = 9).RESULTS: The clinical response rates of radiotherapy, chemotherapy, and radiotherapy plus chemotherapy were 75{\%}, 69{\%}, and 89{\%}, respectively. In addition, the hematologic response rates were 50{\%}, 69{\%}, and 71{\%}, respectively. Among the six patients with limited multiple lesions who underwent radiotherapy, the clinical symptoms were improved in five patients after radiotherapy. The median progression-free survival (PFS) was 51 months, and the median overall survival (OS) was 65 months. In univariate analysis, the administration of chemotherapy was significantly associated with better PFS (p = 0.007) and OS (p = 0.020). In contrast, underlying VEGFe was a significant factor worsening PFS (p = 0.035) and OS (p = 0.008).CONCLUSIONS: Radiotherapy produces a reliable clinical response and is effective in improving POEMS-associated symptoms that are refractory to chemotherapy in selected patients with clustered or limited multiple lesions that can be covered by single radiation field.",
author = "Suh, {Yang Gun} and Kim, {Young Suk} and Suh, {Chang Ok} and Kim, {Yu R.i.} and Cheong, {June Won} and Kim, {Jin S.eok} and Jaeho Cho",
year = "2014",
month = "1",
day = "1",
doi = "10.1186/s13014-014-0265-8",
language = "English",
volume = "9",
journal = "Radiation Oncology",
issn = "1748-717X",
publisher = "BioMed Central",

}

The role of radiotherapy in the management of POEMS syndrome. / Suh, Yang Gun; Kim, Young Suk; Suh, Chang Ok; Kim, Yu R.i.; Cheong, June Won; Kim, Jin S.eok; Cho, Jaeho.

In: Radiation oncology (London, England), Vol. 9, 01.01.2014.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The role of radiotherapy in the management of POEMS syndrome

AU - Suh, Yang Gun

AU - Kim, Young Suk

AU - Suh, Chang Ok

AU - Kim, Yu R.i.

AU - Cheong, June Won

AU - Kim, Jin S.eok

AU - Cho, Jaeho

PY - 2014/1/1

Y1 - 2014/1/1

N2 - BACKGROUND: POEMS syndrome is a paraneoplastic syndrome caused by an underlying plasma cell proliferative disease. In this study, we examined the treatment outcomes and role of radiotherapy in the management of POEMS syndrome.METHODS: In total, 33 patients diagnosed with POEMS syndrome were analyzed. These patients presented with osteosclerotic myeloma (OSM, n = 13), Castleman's disease (CD, n = 4), OSM with CD (n = 10), and vascular endothelial growth factor elevation without gross lesions (VEGFe, n = 6), respectively. The patients were treated by radiotherapy alone (n = 4), chemotherapy alone (n = 16), or a combination thereof (n = 9).RESULTS: The clinical response rates of radiotherapy, chemotherapy, and radiotherapy plus chemotherapy were 75%, 69%, and 89%, respectively. In addition, the hematologic response rates were 50%, 69%, and 71%, respectively. Among the six patients with limited multiple lesions who underwent radiotherapy, the clinical symptoms were improved in five patients after radiotherapy. The median progression-free survival (PFS) was 51 months, and the median overall survival (OS) was 65 months. In univariate analysis, the administration of chemotherapy was significantly associated with better PFS (p = 0.007) and OS (p = 0.020). In contrast, underlying VEGFe was a significant factor worsening PFS (p = 0.035) and OS (p = 0.008).CONCLUSIONS: Radiotherapy produces a reliable clinical response and is effective in improving POEMS-associated symptoms that are refractory to chemotherapy in selected patients with clustered or limited multiple lesions that can be covered by single radiation field.

AB - BACKGROUND: POEMS syndrome is a paraneoplastic syndrome caused by an underlying plasma cell proliferative disease. In this study, we examined the treatment outcomes and role of radiotherapy in the management of POEMS syndrome.METHODS: In total, 33 patients diagnosed with POEMS syndrome were analyzed. These patients presented with osteosclerotic myeloma (OSM, n = 13), Castleman's disease (CD, n = 4), OSM with CD (n = 10), and vascular endothelial growth factor elevation without gross lesions (VEGFe, n = 6), respectively. The patients were treated by radiotherapy alone (n = 4), chemotherapy alone (n = 16), or a combination thereof (n = 9).RESULTS: The clinical response rates of radiotherapy, chemotherapy, and radiotherapy plus chemotherapy were 75%, 69%, and 89%, respectively. In addition, the hematologic response rates were 50%, 69%, and 71%, respectively. Among the six patients with limited multiple lesions who underwent radiotherapy, the clinical symptoms were improved in five patients after radiotherapy. The median progression-free survival (PFS) was 51 months, and the median overall survival (OS) was 65 months. In univariate analysis, the administration of chemotherapy was significantly associated with better PFS (p = 0.007) and OS (p = 0.020). In contrast, underlying VEGFe was a significant factor worsening PFS (p = 0.035) and OS (p = 0.008).CONCLUSIONS: Radiotherapy produces a reliable clinical response and is effective in improving POEMS-associated symptoms that are refractory to chemotherapy in selected patients with clustered or limited multiple lesions that can be covered by single radiation field.

UR - http://www.scopus.com/inward/record.url?scp=84964696443&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964696443&partnerID=8YFLogxK

U2 - 10.1186/s13014-014-0265-8

DO - 10.1186/s13014-014-0265-8

M3 - Article

C2 - 25431020

AN - SCOPUS:84964696443

VL - 9

JO - Radiation Oncology

JF - Radiation Oncology

SN - 1748-717X

ER -